Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Operating Expenses (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Operating Expenses data on record, last reported at $10.6 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 45.72% year-over-year to $10.6 million; the TTM value through Sep 2025 reached $30.8 million, up 22.56%, while the annual FY2023 figure was $23.4 million, 28.12% down from the prior year.
  • Operating Expenses reached $10.6 million in Q3 2025 per CRVS's latest filing, up from $10.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $12.5 million in Q3 2022 and bottomed at $5.6 million in Q3 2023.
  • Average Operating Expenses over 4 years is $7.6 million, with a median of $6.8 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: crashed 55.42% in 2023, then soared 72.87% in 2025.
  • A 4-year view of Operating Expenses shows it stood at $5.7 million in 2022, then dropped by 0.26% to $5.7 million in 2023, then grew by 28.38% to $7.3 million in 2024, then surged by 45.72% to $10.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $10.6 million in Q3 2025, $10.3 million in Q2 2025, and $9.9 million in Q1 2025.